Back to Search Start Over

Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy; an 11-year multi-centre retrospective study

Authors :
de la Court, Jara R.
Woudt, Sjoukje H. S.
Schoffelen, Annelot F.
Heijmans, Jarom
de Jonge, Nick A.
van der Bruggen, Tjomme
Bomers, Marije K.
Lambregts, Merel M. C.
Schade, Rogier P.
Sigaloff, Kim C. E.
Stuart, J. W. T. Cohen
Melles, D. C.
van Dijk, K.
Alzubaidy, A.
Werdmuller, B. F. M.
Blaauw, G. J.
Diederen, B. M. W.
Alblas, H. J.
der Kuil, W. Altorf-van
Bierman, S. M.
de Greeff, S. C.
Groenendijk, S. R.
Hertroys, R.
Kuijper, E. J.
Monen, J. C.
Notermans, D. W.
van den Reek, W. J.
Smilde, A. E.
Wielders, C. C. H.
Zoetigheid, R. E.
van den Bijllaardt, W.
Kraan, E. M.
Mattsson, E. E.
da Silva, J. M.
de Jong, E.
Maraha, B.
van Asselt, G. J.
Demeulemeester, A.
Wintermans, B. B.
van Trijp, M.
Ott, A.
Sinnige, J.
Silvis, W.
Bakker, L. J.
Dorigo-Zetsma, J. W.
Waar, K.
Bernards, A. T.
Hall, M. A. Leversteijn-van
Schaftenaar, E.
Nabuurs-Franssen, M. H.
Wertheim, H.
Bode, L.
van Rijn, M.
Dinant, S.
Pontesilli, O.
de Man, P.
Wong, M.
Muller, A. E.
Renders, N. H.
Bentvelsen, R. G.
Buiting, A. G. M.
Vlek, A. L. M.
Stam, A. J.
Troelstra, A.
Overdevest, I. T. M. A.
van Meer, M. P. A.
dos Santos, C. Oliveira
Wolfhagen, M. J. H. M.
Hematology
Internal medicine
AII - Infectious diseases
Medical Microbiology and Infection Prevention
APH - Quality of Care
Elderly care medicine
APH - Aging & Later Life
Graduate School
General Internal Medicine
CCA - Cancer biology and immunology
AGEM - Amsterdam Gastroenterology Endocrinology Metabolism
CCA - Cancer Treatment and Quality of Life
Clinical Haematology
Experimental Immunology
APH - Health Behaviors & Chronic Diseases
Source :
ISIS-AR study group 2022, ' Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy; an 11-year multi-centre retrospective study ', Annals of Clinical Microbiology and Antimicrobials, vol. 21, no. 1, 54 . https://doi.org/10.1186/s12941-022-00544-0, Annals of Clinical Microbiology and Antimicrobials, 21(1):54. BioMed Central Ltd., Annals of clinical microbiology and antimicrobials, 21(1):54. BioMed Central, Annals of Clinical Microbiology and Antimicrobials, 21(1). BMC
Publication Year :
2022
Publisher :
Springer Science and Business Media LLC, 2022.

Abstract

Objectives Among patients with haematological malignancy, bacteraemia is a common complication during chemotherapy-induced neutropenia. Resistance of gram-negative bacteria (GNB) to third-generation cephalosporins (3GC) is increasing. In order to explore the value of using surveillance cultures to guide empirical treatment e.g. choosing between carbapenem versus ceftazidime- we aimed to assess the distribution of pathogens causing bacteraemia in patients with haematological malignancy, and the proportion of 3GC-resistant GNB (3GC-R GNB) bacteraemia that was preceded by 3GC-R GNB colonization. Methods Using 11 years of data (2008–2018) from the Dutch national antimicrobial resistance surveillance system, we assessed the prevalence of 3GC-R GNB in episodes of bacteraemia, and the proportion of 3GC-R GNB bacteraemia that was preceded by 3GC-R GNB colonization. Colonization was defined as availability of any GNB surveillance isolate in the year before, independent of the causative micro-organism (time-paired isolates). Results We included 3887 patients, representing 4142 episodes of bacteraemia. GNB were identified in 715/4142 (17.3%), of which 221 (30.9%) were 3GC-R GNB. In 139 of these 221 patients a time-paired surveillance culture was available. In 76.2% (106/139) of patients these surveillance cultures already showed 3GC-R GNB isolates in the year prior to the culture date of the 3GC-R GNB positive blood isolate. Conclusions This multi-centre study shows that in patients with haematological malignancy, the majority of 3GC-R GNB bacteraemia is preceded by 3GC-R GNB colonization. Prospective clinical studies are needed to assess the safety and benefits of the use of surveillance-cultures to guide empirical therapy to restrict the empirical use of carbapenems in this population.

Details

ISSN :
14760711
Volume :
21
Database :
OpenAIRE
Journal :
Annals of Clinical Microbiology and Antimicrobials
Accession number :
edsair.doi.dedup.....090e11b56efc1a6cc928f4770cb8377c
Full Text :
https://doi.org/10.1186/s12941-022-00544-0